Abstract: Chemotherapy, a conventional breast cancer treatment, has limitations due to its nonspecific mechanisms and undesirable side effects. Lipid-based nanoparticles (LNPs) have emerged as a versatile and superior platform for targeted breast cancer treatment, offering several distinct advantages over traditional therapies. This class of nanocarriers, which includes solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and liposomes, enhances the bioavailability and stability of therapeutic agents while minimizing systemic toxicity. LNPs can be engineered to precisely target breast cancer cells by exploiting tumor-specific markers, enabling selective delivery of chemotherapeutic agents and reducing off-target effects. SLNs provide controlled drug release and improved drug retention within the tumor, while NLCs offer higher drug-loading capacities and better stability. Liposomes, with their flexible design, allow for the encapsulation of both hydrophilic and hydrophobic drugs and can be modified for active targeting through surface functionalization. These lipid-based carriers also address the challenges of multi-drug resistance (MDR) by enhancing intracellular drug concentration and overcoming efflux mechanisms. In this review, we focus on lipid-based nanoparticles- a subtype of nanoparticles, and their potential advantages as drug delivery systems for breast cancer treatment. Results revealed that lipidbased nanoparticles have shown potential in breast cancer management, these include improved drug efficacy, enhanced ability to overcome cancer therapy resistance, and effective drug carrier for co-loaded drugs.
Read full abstract